On July 8, 2025, Jasper Therapeutics, Inc. announced a corporate reorganization to reduce its workforce by about 50%, focusing on its briquilimab clinical programs, which will cost approximately $1.8 to $2.2 million in severance expenses. Effective August 1, 2025, Chief Medical Officer Dr. Edwin Tucker will depart as part of this restructuring.